RT Journal Article
T1 Clinical Performance of Commercial ISAC 112 Allergen Microarray Versus Noncommercial RIRAAF Platform for the Diagnosis of Plant Food and Olive Pollen Allergies.
A1 Martinez-Aranguren, R
A1 Martinez-Botas, J
A1 Diaz-Perales, A
A1 Villalba, M
A1 de-la-Hoz, B
A1 Gomez, F
A1 Bartra, J
A1 Blanca-Lopez, N
A1 Alvarado, M I
A1 Moya, C
A1 Feo-Brito, F
A1 Alonso, M D
A1 Gonzalez-Mancebo, E
A1 Terrados, S
A1 Garcia, B E
A1 Gamboa, P
A1 Parra, A
A1 D Amelio, C
A1 Goikoetxea, M J
A1 Sanz, M L
K1 Allergy
K1 Component-resolved diagnosis
K1 ISAC 112
K1 Microarray
K1 sIgE
K1 Diagnóstico basado en componentes
K1 Alergia
AB The combination of molecular biology and technological advances in recent years has enabled the development of new methods for determining serum specific IgE (sIgE) [1] to different allergens using a single determination method with minimal quantities of allergen and serum [2]. However, to achieve an accurate diagnostic assessment, it is still important to apply an adequate panel of allergens [3]. The ImmunoCAP ISAC 112 microarray (Thermo Fisher Scientific) is the only commercially available allergenic protein microarray, but its current panel of allergens does not seem to have the best accuracy when diagnosing food or pollen allergies in certain regions [3]. Indeed, some authors have even suggested including other allergens [3,4]. As part of the Spanish National Research Network of adverse reactions to allergens and drugs (RIRAAF), our team recently developed a new allergenic protein microarray model.
PB Esmon Publicidad
SN 1018-9068
YR 2015
FD 2015-11-23
LK http://hdl.handle.net/10668/10198
UL http://hdl.handle.net/10668/10198
LA en
NO Martínez-Aranguren R, Martínez-Botas J, Díaz-Perales A, Villalba M, de la Hoz B, Gómez F, et al. Clinical Performance of Commercial ISAC 112 Allergen Microarray Versus Noncommercial RIRAAF Platform for the Diagnosis of Plant Food and Olive Pollen Allergies. J Investig Allergol Clin Immunol. 2016;26(3):185-7
NO This research was financially supported by grants PI 11/01634 and RD12/0013/00010 from the Spanish Research Network on Adverse Reactions to Allergens and Drugs (RIRAAF; Red de Investigación de Reacciones Adversas a Alérgenos y Fármacos) within the Instituto de Salud Carlos III.
DS RISalud
RD Apr 9, 2025